Related references
Note: Only part of the references are listed.Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma
Zhiheng Cheng et al.
ANNALS OF HEMATOLOGY (2018)
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer
Yoshimi Imawari et al.
CANCER SCIENCE (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ubiquitylation of MFHAS1 by the ubiquitin ligase praja2 promotes M1 macrophage polarization by activating JNK and p38 pathways
Jing Zhong et al.
CELL DEATH & DISEASE (2017)
ALK-positive Large B-cell Lymphoma A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature
Zenggang Pan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Whole Exome Sequencing of Relapsed/Refractory Patients Expands the Repertoire of Somatic Mutations in Diffuse Large B-Cell Lymphoma
Sylvain Mareschal et al.
GENES CHROMOSOMES & CANCER (2016)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M. Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Sara Redaelli et al.
ONCOTARGET (2016)
MFHAS1 promotes colorectal cancer progress by regulating polarization of tumor-associated macrophages via STAT6 signaling pathway
Wankun Chen et al.
ONCOTARGET (2016)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas
Leandro Cerchietti et al.
PLOS ONE (2011)
Human leucine-rich repeat proteins: a genome-wide bioinformatic categorization and functional analysis in innate immunity
Aylwin C. Y. Ng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature
Brady Beltran et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8
H Tagawa et al.
ONCOGENE (2004)
Share Paper
